title: Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
authors.forename: Diego J
authors.initials: DJ
authors.lastname: Bedoya
authors.forename: Nicholas
authors.initials: N
authors.lastname: Mitsiades
mesh_terms: D000069501:Abiraterone Acetate; D000726:Androgen Antagonists / Q000627:therapeutic use; D059002:Androgen Receptor Antagonists / Q000627:therapeutic use; D000728:Androgens / Q000378:metabolism; D000730:Androstadienes / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D011944:Receptors, Androgen / Q000378:metabolism; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*
chemical_list: C410798:AR protein, human; D000726:Androgen Antagonists; D059002:Androgen Receptor Antagonists; D000728:Androgens; D000730:Androstadienes; D004791:Enzyme Inhibitors; D005938:Glucocorticoids; D011944:Receptors, Androgen; D013254:Steroid 17-alpha-Hydroxylase; D000069501:Abiraterone Acetate